Use of Multiple Sclerosis Drugs Among Pregnant Women

Project Title Use of Multiple Sclerosis Drugs Among Pregnant Women
Date Posted
Thursday, December 6, 2018
Project ID
cder_mpl1p_wp009
Status
Complete
Deliverables
Related Links
Description

This report contains estimates of multiple sclerosis (MS) drug use before, during, and after pregnancies resulting in a live-born delivery, among women in the Sentinel Distributed Database (SDD). Data from January 1, 2001 to August 31, 2017 from 16 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on November 20, 2017.

Medical Product
alemtuzumab
daclizumab
dalfampridine
dimethyl fumarate
fingolimod
glatiramer acetate
interferon beta-1A
interferon beta-1A/albumin
interferon beta-1B
mitoxantrone
natalizumab
peginterferon beta-1a
teriflunomide
Health Outcome
pregnancy
Population / Cohort
Pregnant women and women of reproductive age
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Sentinel Distributed Database (SDD)
FDA Center
CDER